hVIVO plc
OTC: OPORF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yamin Mohammed Khan
- Employees
- 301
- Headquarters
- London, United Kingdom
- IPO year
- 2020
- Market cap
- $75.4M
- Website
- https://www.hvivo.com
Loading OPORF…
Loading profile data…Frequently asked questions about OPORF
What does hVIVO plc (OPORF) do?
hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials. The company extends its services to a varied clientele, encompassing major pharmaceutical and biotechnology firms,...
Where does OPORF trade?
hVIVO plc (OPORF) trades on the Other OTC.
What sector is OPORF in?
hVIVO plc (OPORF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of hVIVO plc?
Yamin Mohammed Khan is the chief executive officer of hVIVO plc (OPORF).
Where is hVIVO plc headquartered?
hVIVO plc is headquartered in United Kingdom.
Does OPORF pay a dividend?
Yes — hVIVO plc (OPORF) paid a trailing twelve-month dividend of USD 0.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did OPORF go public?
hVIVO plc (OPORF) completed its initial public offering in 2020.